Industry Reports

Johnson & Johnson completes acquisition of AliosBioPharma for $1.75bn

US-based Johnson & Johnson (J&J) has completed the acquisition of a privately held clinical stage biopharmaceutical company, AliosBioPharma, for $1.75bn in cash. Based in California, US, AliosBioPharma develops therapies for the treatment of viral diseases. The...

Aegerion to acquire AstraZeneca’s lipodystrophy treatment Myalept for $325m

Aegerion Pharmaceuticals has signed an agreement to acquire an orphan product Myalept (metreleptin for injection) from AstraZeneca. AstraZeneca will receive $325m upfront payment to divest the rights to develop, manufacture and commercialise Myalept, subject to an...

Johnson & Johnson Reports 2014 Second-Quarter Results

Sales of $19.5 Billion increased 9.1% Versus 2013 Second Quarter; Second-Quarter EPS was $1.51 Excluding Special Items, 2014 Second-Quarter EPS of $1.66 increased 12.2%* Johnson & Johnson today announced sales of $19.5 billion for the second...

Pivotal Therapeutics Announces First Quarter Financial Results

Pivotal Therapeutics Inc. , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014.  All dollar amounts referenced...

China Nepstar Chain Drugstore Ltd. Reports First Quarter 2014 Financial Results

China Nepstar Chain Drugstore Ltd., a leading retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the first quarter ended March 31, 2014. Financial Highlights...

Can-Fite Reports First Quarter 2014 Results

Can-Fite BioPharma Ltd. , a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the first quarter ended March 31, 2014. Dr. Pnina Fishman,...

Adocia announces financial results for 2013

Adocia announces today its annual financial results for 2013. The financial statements were approved by the board of directors on March 21, 2014 and will be submitted to the shareholders for approval during the next general meeting on June...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read